Additionally, the administration of GLP-1RA was associated with reduction in glomerular sclerosis via the activation of AMPK and endothelial nitric oxide synthase (eNOS) with consequent decrease in urinary albumin; activation of autophagy through suppression of the mammalian target of rapamycin (mTOR) was described as well [49]. The gene discussed is NOS3; the disease is Glomerular sclerosis.